Vnitr Lek 2026, 72(3):144-147 | DOI: 10.36290/vnl.2026.031

Recent advances in biologic therapy of allergic diseases

Mojmír Račanský

Oddělení alergologie a klinické imunologie, FN Olomouc

Ústav imunologie, Lékařská fakulta, Univerzita Palackého v Olomouci

Allergic diseases are showing a continuously rising prevalence worldwide. It is estimated that 20-40 % of the global population suffer from some form of allergic condition. According to data from the World Allergy Organization affiliated with the World Health Organization, roughly one in five people are affected. The severity of allergic diseases varies. However, all forms impact the daily lives of those affected - from seasonal allergic rhinitis, through various manifestations of atopic dermatitis and food allergies, to severe bronchial asthma. Severe forms of allergic diseases considerably diminish patients' quality of life. Their management is challenging and often requires a comprehensive, interdisciplinary approach. For many years, no targeted therapies were available for such conditions. In recent decades, advancements in scientific research and an improved understanding of key pathophysiological mechanisms have enabled effective treatment even for patients in whom conventional therapies have failed. With biologic therapy, many patients can return to normal life and are no longer compelled to adjust their daily activities to their disease. Currently, targeted therapies are available for patients with severe bronchial asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, and eosinophilic oesophagitis, and new indications along with novel biologic agents continue to emerge.

Keywords: allergic diseases, Th2 inflammation, biologic treatment.

Accepted: April 23, 2026; Published: May 18, 2026  Show citation